Insider Cluster (2 insiders) ·Filed Aug 13, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $424K total
Actionable Insight • Neutral

The insider sales are routine in size and pattern (option exercise + sell-to-cover). No material signal for traders. Monitor next 10-Q for any fundamental deterioration, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
UTHR ▼ -0.83% at T+20d
NEUTRAL call ✗ call lost -0.83% · α vs SPY +0.92% · entry $501.27 → $497.11
Next anchor: T+60d in 5w
Latest observation: T+32 +1.50% FF3 residual α
Entry anchored
Aug 12, 04:47 PM ET
via 1-min bar
T+1d
-0.31%
call -0.31% · α -0.11%
$499.73
settled 7w ago
T+5d
+3.94%
call +3.94% · α +5.90%
$521.00
settled 6w ago
T+20d
-0.83%
call -0.83% · α +0.92%
$497.11
settled 22d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$6.35M in open-market shares over a 7-day window following the Q2 2026 earnings release. The total represents only 0.03% of UTHR's $21.9B market cap, making the cluster economically trivial despite the CEO's high-profile status.

Key Financial Metrics

Direction
selling
Total Value
$6.3M
Insiders
2

Key Facts

  • CEO Rothblatt sold ~11,550 shares for ~$5.95M on Aug 11-12, 2026, after exercising 19,000 options (9,500 cash at $135.42, 9,500 non-cash).
  • EVP Mahon sold 780 shares for $404K on Aug 6, 2026.
  • Total open-market sales of ~$6.35M equal 0.029% of UTHR's $21.9B market cap.
  • Sales occurred 4-7 days after UTHR reported Q2 2026 revenue of $783.3M (missed consensus $804.6M) but EPS of $7.27 (beat $6.86).

Financial Impact

Negligible — $6.35M in insider sales is 0.03% of market cap, well below the 0.1% materiality threshold.

Risk Factors

  • CEO selling after a revenue miss could indicate personal portfolio rebalancing, but the amount is too small to suggest a bearish view.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1786691077999
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$571.38 (+14.20%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$571.38 (+14.94%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$571.38 (+13.40%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$571.38 (+12.74%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$571.38 (+17.18%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$571.38 (+17.05%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$571.38 (+10.85%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$571.38 (+8.23%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Showing 10 of 91

US Market Status

Market Open — Closes in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 14, 2026